

Ghassan K Abou-Alfa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3124446/publications.pdf>

Version: 2024-02-01

163
papers

13,509
citations

53794

45
h-index

24982

109
g-index

163
all docs

163
docs citations

163
times ranked

11955
citing authors

#	ARTICLE	IF	CITATIONS
1	Equipoise, drug development, and biliary cancer. <i>Cancer</i> , 2022, 128, 944-949.	4.1	3
2	Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 38-47.	7.7	20
3	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 77-90.	10.7	526
4	Reconciling the prospect of disease progression with goals and expectations: Development and validation of a measurement model in advanced cancer. <i>Psycho-Oncology</i> , 2022, , .	2.3	0
5	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
6	First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers. <i>Liver Cancer</i> , 2022, 11, 268-277.	7.7	7
7	A framework for fibrolamellar carcinoma research and clinical trials. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 328-342.	17.8	23
8	Mouse characteristics that affect establishing xenografts from hepatocellular carcinoma patient biopsies in the United States. <i>Cancer Medicine</i> , 2022, 11, 602-617.	2.8	1
9	Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. <i>Hepatology</i> , 2022, 76, 1649-1659.	7.3	18
10	Progression-Free Survival in Patients With Cholangiocarcinoma With or Without <i>FGF/FGFR</i> Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response. <i>JCO Precision Oncology</i> , 2022, 6, e2100414.	3.0	12
11	Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial. <i>European Journal of Cancer</i> , 2022, 168, 91-98.	2.8	3
12	Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. <i>Cancer</i> , 2022, 128, 2958-2966.	4.1	2
13	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, 1, .		298
14	PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an <i>FGFR2</i> gene fusion/rearrangement.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4171-TPS4171.	1.6	6
15	Targeting <i>HER2</i> mutation-“positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4079-4079.	1.6	11
16	Clinical and genomic characterization of <i>ERBB2</i> -altered gallbladder cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4114-4114.	1.6	2
17	Immunogenomic characterization of biliary tract cancers: Biomarker enrichment for benefit to immune checkpoint blockade.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4083-4083.	1.6	0
18	Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4074-4074.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2022, 40, 4110-4110.	1.6	0
20	Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses. Annals of Surgical Oncology, 2022, 29, 6815-6826.	1.5	2
21	Hepatocellular carcinoma, novel therapies on the horizon. Chinese Clinical Oncology, 2021, 10, 12-12.	1.2	12
22	A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2021, 39, TPS349-TPS349.	1.6	10
23	Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations. JCO Precision Oncology, 2021, 5, 44-50.	3.0	20
24	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 2200-2208.	7.0	51
25	Effect of FGFR2 alterations on survival in patients receiving systemic chemotherapy for intrahepatic cholangiocarcinoma.. Journal of Clinical Oncology, 2021, 39, 303-303.	1.6	15
26	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	2.1	51
27	Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma. Cancer Medicine, 2021, 10, 3059-3067.	2.8	19
28	Genetic predictor of severe sorafenib-induced diarrhea and hand-foot syndrome (HFS).. Journal of Clinical Oncology, 2021, 39, 3030-3030.	1.6	1
29	T-cell receptor pharmacodynamics associated with survival and response to tremelimumab (T) in combination with durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology, 2021, 39, 4087-4087.	1.6	5
30	First-in-human phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of oral GNS561, a palmitoyl-protein thioesterase 1 (PPT1) inhibitor, in patients with primary and secondary liver malignancies.. Journal of Clinical Oncology, 2021, 39, e16175-e16175.	1.6	3
31	Provision of subspecialized expert oncology (SEO) opinions using Navya Cancer Data Model (NCDM), a technology-based platform: Prospective study to facilitate access to care.. Journal of Clinical Oncology, 2021, 39, 6580-6580.	1.6	0
32	Computational extraction and analysis of de-identified medical records to characterize hyperammonemia in patients with fibrolamellar carcinoma (FLC).. Journal of Clinical Oncology, 2021, 39, e16169-e16169.	1.6	0
33	Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202.. Journal of Clinical Oncology, 2021, 39, 4086-4086.	1.6	18
34	Hepatocellular Carcinoma in Sub-Saharan Africa. JCO Global Oncology, 2021, 7, 756-766.	1.8	25
35	Novel non-protein biomarkers for early detection of hepatocellular carcinoma. Engineering, 2021, 7, 1369-1369.	6.7	1
36	Ablative radiation therapy for hepatocellular carcinoma is associated with reduced treatment- and tumor-related liver failure and improved survival. Journal of Gastrointestinal Oncology, 2021, 12, 1743-1752.	1.4	6

#	ARTICLE	IF	CITATIONS
37	Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study. <i>Cancer</i> , 2021, 127, 4585-4593.	4.1	7
38	Pancreas cancer and <i>BRCA</i> : A critical subset of patients with improving therapeutic outcomes. <i>Cancer</i> , 2021, 127, 4393-4402.	4.1	24
39	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2021, 22, 1290-1300.	10.7	178
40	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
41	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2991-3001.	1.6	257
42	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation. <i>JAMA Oncology</i> , 2021, 7, 1669.	7.1	194
43	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with <i>FGFR2</i> fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 803-815.	8.1	205
44	Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. <i>Lancet Oncology</i> , The, 2021, 22, 1560-1572.	10.7	118
45	Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	56
46	Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 1460-1469.	3.7	254
47	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements. <i>Future Oncology</i> , 2020, 16, 2385-2399.	2.4	96
48	Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver. <i>Cancer</i> , 2020, 126, 4126-4135.	4.1	5
49	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 4317-4345.	1.6	350
50	Ivosidenib for advanced <i>IDH1</i> -mutant cholangiocarcinoma – Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e371.	10.7	4
51	<i>NRF2</i> Dysregulation in Hepatocellular Carcinoma and Ischemia: A Cohort Study and Laboratory Investigation. <i>Radiology</i> , 2020, 297, 225-234.	7.3	15
52	ESMO presidential symposium wrap up: the ClarIDHy trial. <i>ESMO Open</i> , 2020, 5, e000699.	4.5	0
53	Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. <i>Cancer Medicine</i> , 2020, 9, 7453-7459.	2.8	11
54	Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma. <i>Advances in Therapy</i> , 2020, 37, 2678-2695.	2.9	37

#	ARTICLE	IF	CITATIONS
55	A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma. <i>Oncologist</i> , 2020, 25, 925-e1603.	3.7	17
56	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 796-807.	10.7	620
57	Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2020, 25, e1825-e1836.	3.7	13
58	Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 671-684.	10.7	923
59	Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. <i>Oncologist</i> , 2020, 25, e1837-e1845.	3.7	21
60	Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial. <i>Future Oncology</i> , 2020, 16, 2375-2384.	2.4	62
61	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 4795-4804.	7.0	58
62	Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. <i>Cancer</i> , 2020, 126, 1995-2002.	4.1	26
63	Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. <i>Cancer Treatment Reviews</i> , 2020, 86, 101998.	7.7	25
64	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. <i>Clinical Cancer Research</i> , 2020, 26, 3239-3247.	7.0	135
65	Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4508-4508.	1.6	86
66	A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4591-4591.	1.6	5
67	Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA. <i>Human Pathology</i> , 2019, 83, 1-6.	2.0	14
68	Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 711-720.	8.1	161
69	Immune checkpoint inhibitors for hepatocellular carcinoma. <i>Cancer</i> , 2019, 125, 3312-3319.	4.1	90
70	Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution. <i>Hpb</i> , 2019, 21, 1541-1551.	0.3	16
71	Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. <i>Cancer</i> , 2019, 125, 4426-4434.	4.1	49
72	Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1582.	7.1	91

#	ARTICLE	IF	CITATIONS
73	Ramucirumab and the controversial role of α -fetoprotein in hepatocellular carcinoma. <i>Lancet Oncology</i> , The, 2019, 20, 177-179.	10.7	8
74	A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5202-5211.	7.0	26
75	Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma?. <i>Digestive Diseases and Sciences</i> , 2019, 64, 918-927.	2.3	26
76	–Road map for fibrolamellar carcinoma: progress and goals of a diversified approach–; <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 41-48.	3.7	5
77	A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2019, 24, 161-e70.	3.7	12
78	Genomic Characterization of <i>ERBB2</i> -Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	3.0	23
79	An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2019, 24, 747-e218.	3.7	72
80	Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 937-945.	7.0	22
81	Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations. <i>Cancer</i> , 2019, 125, 575-585.	4.1	34
82	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 2116-2126.	7.0	390
83	Evaluation and management of incidental gallbladder cancer. <i>Chinese Clinical Oncology</i> , 2019, 8, 37-37.	1.2	13
84	Biliary tract cancer prognostic and predictive genomics. <i>Chinese Clinical Oncology</i> , 2019, 8, 42-42.	1.2	15
85	Systemic therapy for gallbladder cancer. <i>Chinese Clinical Oncology</i> , 2019, 8, 44-44.	1.2	27
86	Gallbladder cancer, a forgotten global cancer problem. <i>Chinese Clinical Oncology</i> , 2019, 8, 30-30.	1.2	0
87	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1067-1074.	6.3	170
88	Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. <i>Annals of Oncology</i> , 2018, 29, 1402-1408.	1.2	151
89	Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype–Phenotype Features–An Entity With an Increasing Incidence?. <i>Clinical Colorectal Cancer</i> , 2018, 17, e315-e321.	2.3	13
90	Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 944-951.	2.4	4

#	ARTICLE	IF	CITATIONS
91	Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers. <i>Seminars in Oncology</i> , 2018, 45, 116-123.	2.2	9
92	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	1.6	524
93	Cabozantinib in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 1384-1385.	27.0	13
94	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. <i>Cancer Discovery</i> , 2018, 8, 1540-1547.	9.4	138
95	Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. <i>Clinical Cancer Research</i> , 2018, 24, 4154-4161.	7.0	348
96	A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 429-440.	2.3	35
97	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 54-63.	27.0	1,677
98	I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. <i>EJNMMI Research</i> , 2018, 8, 20.	2.5	17
99	A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4146-TPS4146.	1.6	10
100	Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 421-429.	2.3	19
101	Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. <i>Liver Cancer</i> , 2017, 6, 16-26.	7.7	97
102	The role (if any) of chemotherapy in hepatocellular carcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 387-389.	8.1	7
103	Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 29-36.	2.3	24
104	Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2017, 22, 780-e65.	3.7	18
105	Hepatocellular carcinoma in patients with HIV. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 20-25.	3.8	13
106	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. <i>Clinical Cancer Research</i> , 2017, 23, 6094-6100.	7.0	161
107	Reply to A. Braillon, M. Boulin et al, and J.-H. Zhong et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 258-259.	1.6	1
108	Treatment options after sorafenib failure in patients with hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 273-279.	8.9	34

#	ARTICLE	IF	CITATIONS
109	Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, E65-E72.	1.4	4
110	Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4015-4015.	1.6	71
111	Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4073-4073.	1.6	133
112	ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4142-TPS4142.	1.6	17
113	Acute myeloid leukemia masquerading as hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, E31-E35.	1.4	6
114	Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 819-827.	1.4	17
115	Advanced Hepatocellular Cancer: the Current State of Future Research. <i>Current Treatment Options in Oncology</i> , 2016, 17, 43.	3.0	50
116	Immunotherapy in hepatocellular carcinoma: Primed to make a difference?. <i>Cancer</i> , 2016, 122, 367-377.	4.1	112
117	Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 65, 289-295.	3.7	89
118	Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. <i>Journal of Clinical Oncology</i> , 2016, 34, 2046-2053.	1.6	307
119	Pancreatic neuroendocrine tumor with aneurysms of the gastroduodenal artery: a case report. <i>Clinical Imaging</i> , 2016, 40, 228-231.	1.5	1
120	Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016, 34, 192-192.	1.6	69
121	Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 437-437.	1.6	3
122	Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2016, 5, 66-66.	1.2	33
123	Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. <i>Chinese Clinical Oncology</i> , 2016, 5, 62-62.	1.2	131
124	Systemic therapy for biliary cancers. <i>Chinese Clinical Oncology</i> , 2016, 5, 65-65.	1.2	13
125	Preface: special issue on biliary cancer. <i>Chinese Clinical Oncology</i> , 2016, 5, E2-E2.	1.2	1
126	Hepatic adenoma among adult survivors of childhood cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 117-117.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Overall survival and clinical characteristics of BRCA germline/somatic cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2016, 34, 244-244.	1.6	0
128	Hepatocellular Carcinoma Tumor Board: Making Sense of the Technologies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e213-e220.	3.8	2
129	Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread. Journal of Vascular and Interventional Radiology, 2015, 26, 1112-1121.	0.5	8
130	Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).. Journal of Clinical Oncology, 2015, 33, TPS496-TPS496.	1.6	5
131	Liver resection for metastatic colorectal leiomyosarcoma: a single center experience. Journal of Gastrointestinal Oncology, 2015, 6, E70-6.	1.4	15
132	Liver-directed conversion therapy in metastatic colon cancer. Journal of Gastrointestinal Oncology, 2015, 6, 322-8.	1.4	1
133	"This is not me": patient, family, cultural and clinician considerations in cases of severe cancer-related debility. Journal of Gastrointestinal Oncology, 2015, 6, 589-93.	1.4	0
134	The use of genetic alterations in the development of liver cancer drugs. Clinical Advances in Hematology and Oncology, 2015, 13, 826-8.	0.3	0
135	Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer. Clinical Cancer Research, 2014, 20, 5281-5289.	7.0	49
136	A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. Journal of Hepatology, 2014, 60, 319-324.	3.7	83
137	Sorafenib use in hepatocellular carcinoma: More questions than answers. Hepatology, 2014, 60, 15-18.	7.3	28
138	Treating advanced hepatocellular carcinoma: How to get out of first gear. Cancer, 2014, 120, 3122-3130.	4.1	33
139	The role of tyrosine kinase inhibitors in hepatocellular carcinoma. Clinical Advances in Hematology and Oncology, 2014, 12, 36-41.	0.3	13
140	The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?. Lancet Oncology, The, 2013, 14, e283-e288.	10.7	40
141	Approaching the era of personalised therapy for liver cancer?. Lancet Oncology, The, 2013, 14, 7-8.	10.7	5
142	Shaping the Future Management of Hepatocellular Carcinoma. Seminars in Liver Disease, 2013, 33, S20-S24.	3.6	5
143	Risk factors for developing hepatocellular carcinoma in Egypt. Chinese Clinical Oncology, 2013, 2, 43.	1.2	35
144	Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointestinal Cancer Research: GCR, 2013, 6, 3-9.	0.7	50

#	ARTICLE	IF	CITATIONS
145	Status of hepatocellular carcinoma in Gulf region. Chinese Clinical Oncology, 2013, 2, 42.	1.2	4
146	Hepatocellular carcinoma: what is happening everywhere?. Chinese Clinical Oncology, 2013, 2, 31.	1.2	0
147	A Man with Klinefelter's Syndrome and New Abdominal Distension: A Discussion of Evaluation and Management. Journal of Gastrointestinal Cancer, 2012, 43, 314-318.	1.3	2
148	Retrospective review of doxorubicin plus sorafenib as second-line therapy in hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2012, 30, 298-298.	1.6	4
149	Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 321-325.	1.3	97
150	MicroRNA, hypoxic stress and hepatocellular carcinoma: Future directions. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1586-1588.	2.8	3
151	PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2011, 68, 539-545.	2.3	29
152	A Woman with Remotely Treated Pancreas Cancer and New Abdominal Pain: A Discussion of Evaluation and Management. Journal of Gastrointestinal Cancer, 2011, 42, 236-240.	1.3	1
153	Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma. JAMA - Journal of the American Medical Association, 2010, 304, 2154.	7.4	412
154	Commentary: Sorafenib "The End of a Long Journey in Search of Systemic Therapy for Hepatocellular Carcinoma, or the Beginning?. Oncologist, 2009, 14, 92-94.	3.7	10
155	Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301. Journal of Clinical Oncology, 2009, 27, 1800-1805.	1.6	195
156	Selection of Patients with Hepatocellular Carcinoma for Sorafenib. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 397-403.	4.9	31
157	The impact of new data in the treatment of advanced hepatocellular carcinoma. Current Oncology Reports, 2008, 10, 199-205.	4.0	25
158	New agents in hepatocellular carcinoma. Clinical Advances in Hematology and Oncology, 2008, 6, 423-4.	0.3	0
159	Treatment of hepatocellular carcinoma: considerations regarding etiology and molecular biology. Gastrointestinal Cancer Research: GCR, 2007, 1, S85-9.	0.7	0
160	Hepatocellular Carcinoma: Molecular Biology and Therapy. Seminars in Oncology, 2006, 33, 79-83.	2.2	41
161	Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2006, 24, 4441-4447.	1.6	254
162	Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 2006, 24, 4293-4300.	1.6	1,144

#	ARTICLE	IF	CITATIONS
163	A Phase II Study of Intravenous Exatecan Administered Daily for 5 Days, Every 3 Weeks to Patients With Biliary Tract Cancers. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 334-339.	1.3	10